Catlaw buttercup

Synopsis

Catlaw Buttercup (Ranunculus ternatus Thunb.): A Comprehensive Reference

1. Identity and Botanical Classification

Botanical and Pharmacognostic Names

Catlaw buttercup is the English common name for the medicinal root drug derived from Ranunculus ternatus Thunb., a species within the family Ranunculaceae (the buttercup family). Radix Ranunculi ternati (RRT), known in Chinese as Mao-Zhao-Cao (毛爪草), is the dried root of Ranunculus ternatus Thunb., a plant in the Ranunculaceae family and belonging to the genus Ranunculus. The genus name Ranunculus derives from the Latin for "little frog," — the diminutive of rana — which probably refers to many species being found near water, like frogs.

The name "catlaw buttercup" refers directly to the plant's root morphology: it is spindle-shaped and clustered, resembling a cat's claw. The plant is also known in the literature and in trade as catclaw buttercup or catclaw buttercup root.

Ranunculus is a genus of over 1,700 species of plants. Buttercup is the common name for any of the members in the large plant genus Ranunculus in the flowering plant family Ranunculaceae, typically characterized by glossy yellow or white flowers with a yellow center. Within this large genus, R. ternatus is distinguished by its tuberous roots, which are the part used medicinally.

Plant Description and Geographic Distribution

Ranunculus ternatus is a plant species belonging to the buttercup family. This perennial herb is native to various parts of Asia, including China, where it has been utilized in traditional medicine for centuries. Radix Ranunculi ternati (RRT) is widely used as traditional and folk medicine distributed in China, as well as in Kyushu and Shikoku in Japan. The plant is widely distributed across multiple Chinese provinces, including Guizhou, Yunnan, and Henan, making it cheap and easy to obtain.

Pharmacopoeial Status

As a species within the Ranunculaceae family, Ranunculus ternatus has been officially recognized in the Chinese Pharmacopoeia since 1977. Its dried root has traditionally been used in Chinese medicine to treat conditions such as stomatitis and tuberculosis.

Common Forms and Preparations

The medicinal portion is exclusively the root. The genus Ranunculus has a long history of traditional medicinal uses, mainly for resolving phlegm and swelling, dissipating knots, and detoxification. The whole herbs of all the plants except R. ternatus (roots are used) are used for medicinal purposes.

Modern commercial preparations of catlaw buttercup root extract include dried and powdered root, standardized extracts calibrated to alkaloid content, and pharmaceutical capsule formulations. The preparations recorded in Chinese patent medicine prescriptions with R. ternatus as the main ingredient are Maozhuacao Capsule and Yifei Zhike Capsule. Maozhuacao Capsule is a pure TCM preparation made from the pellets of R. ternatus extracted by modern purification technology. This capsule possesses numerous advantages such as easy access, safety, validity, and affordable price.

In the dietary supplement trade, extract products are typically standardized to alkaloid content (e.g., 3%, 4%, or 5% alkaloids) and are also sold in volumetric ratios such as 4:1, 5:1, 10:1, and 20:1 concentrated dry extracts, with testing by HPLC or UV spectrophotometry. Other available forms include tinctures (liquid extracts that can be added to water or other beverages), topical preparations (creams or ointments for external use), and herbal teas (dried root pieces or powder used to make infusions).

2. Traditional and Historical Use

Traditional Chinese Medicine (TCM)

The use of R. ternatus root in Traditional Chinese Medicine is the most extensively documented historical application of catlaw buttercup. TCM believes that R. ternatus is warm in nature, sweet, and acrid in taste, and enters the liver and lung meridians. Based on experience, predecessors conclude that R. ternatus plays a vital role in clearing away heat, detoxification, relieving cough, softening phlegm, dissipating knots, and reducing swelling.

In Traditional Chinese Medicine (TCM), Mao Zhao Cao belongs to the "Herbs that clear Heat and relieve Toxicity" category. Herbs in this category are used to clear inflammatory and infectious conditions, referred to as "Internal Heat" in TCM. Its main actions according to TCM are to dispel phlegm and disperse nodules, and to detoxify and reduce swellings.

The conditions for which TCM practitioners have historically prescribed Mao Zhao Cao are wide-ranging. Primary conditions or symptoms for which Mao Zhao Cao may be prescribed by TCM doctors include: scrofula, subcutaneous nodes, pulmonary tuberculosis, malaria, snake bites, insect bites, lung cancer, lymphatic tuberculosis, laryngitis, and hemorrhoids.

It can be used when lymphatic tuberculosis has not ulcerated, but it cannot be used after it has ulcerated, as this may turn into sores. This historically recognized contraindication illustrates that TCM practitioners understood both the therapeutic potential and the limitations of the herb.

Traditional preparation involved the roots or tubers: collect the roots or tubers in the spring, remove the fibrous roots and mud, then dry in the sun. A TCM ingredient is almost never eaten on its own but as part of a formula containing several ingredients that act together.

The Pharmacopoeia of the People's Republic of China formalizes these traditional functions. According to the Pharmacopoeia of the People's Republic of China, RT possesses functions such as "Hua Tan San Jie" (phlegm-resolving and nodule-dispersing) and "Jie Du Xiao Zhong" (detoxifying and reducing swelling).

Traditional use of R. ternatus specifically for tuberculosis has a deep historical basis. TCM has been used in treating tuberculosis for more than 2000 years. Furthermore, folk use of R. ternatus includes treatment of various symptoms such as lymph nodes, poisonous swelling, snake bites, and furunculosis in some countries.

Japanese Ethnobotanical Use

Beyond China, the root has also been employed as a folk medicine in Japan. Radix Ranunculi ternati (RRT) is widely used as traditional and folk medicine distributed in China, as well as in Kyushu and Shikoku in Japan. The extent of documented traditional Japanese use is less detailed in the available English-language literature.

European and Western Folk Use of the Broader Ranunculus Genus

While catlaw buttercup's traditional history is predominantly Asian, the broader history of the Ranunculus genus in Western folk medicine is relevant context. Creeping buttercup has a long history of use in folk medicine for centuries; traditionally, it was used to treat wounds, skin conditions, and digestive problems. Nicholas Culpeper, the famous 17th-century herbalist, noted that buttercups caused blistering and were sometimes used to draw out poison or "bad humours." These Western applications reflect the same vesicant chemistry common to the genus, exploited therapeutically under careful preparation.

3. Key Constituents and Active Compounds

Overview of Phytochemical Diversity

Catlaw buttercup root is phytochemically rich and complex. Up to 103 chemical constituents have been isolated from RRT. These compounds are mainly divided into eight classes: glycosides, organic acids, esters, sterols, flavonoids, alkaloids, volatile oils, and miscellaneous compounds.

A more detailed summary identifies the following major compound classes: RT is a medicinal plant rich in bioactive compounds, including alkaloids, polyphenols, flavonoids, triterpenoids, and polysaccharides.

Alkaloids

Alkaloids represent the most pharmacologically studied class of compounds in R. ternatus. Among the bioactive compounds in RT, alkaloids have received the most attention for their anti-cancer properties. Uniquely characterized alkaloids include the indolopyridoquinazoline alkaloid glycosides. The indolopyridoquinazoline alkaloids — ternatusine A, ternatoside A, ternatoside B, ternatoside C, and ternatoside D — were identified as bioactive components of R. ternatus. Ternatosides C and D, in particular, are alkaloidal glycosides: two new indolopyridoquinazoline alkaloidal glycosides, 11-O-beta-D-glucopyranosyl rutaecarpine (ternatoside C) and 11-O-alpha-L-rhamnosyl-(1→6)-beta-D-glucopyranosyl rutaecarpine (ternatoside D), were isolated from the roots of Ranunculus ternatus.

Glycosides and Phenolics

Several novel glycosides unique to this species have been reported. Two new glycosides named ternatoside A and ternatoside B, with four known constituents — sternbin, methylparaben, 4-O-D-glucopyranosyl-p-coumaric acid, and linocaffein — were isolated from the roots of Ranunculus ternatus. Additionally, R. ternatus ethyl acetate extract constituents include sternbin, methylparaben, 3-[(4-O-d-glucopyranosyl)-phenyl]-2-propenoic acid, linocaffein, β-d-glucose, robustaflavone-4′-methylether, kayaflavone, podocarpus flavone A, bilobetin, isoginkgetin, amentoflavone, ternatoside A, ternatoside B, and 4-O-d-glucopyranosyl-p-coumaric acid.

Triterpenes and Sterols

Several biologically active triterpenes have been isolated. A new triterpene, 3β-acetoxy-(20S, 22E)-dammaran-22-en-25-ol, was isolated along with five known triterpenes — ursolic acid, oleanolic acid, betulinic acid, 3-epiocotillol acetate, and dimmarenediol II acetate — from Radix Ranunculus ternati. Of particular interest is β-sitosterol, which has been confirmed as a major constituent: our study confirms the therapeutic value of β-sitosterol, a major constituent of Ranunculus ternatus Thunb., in hepatic fibrosis and identifies its underlying mechanisms.

The quercetin, ursolic acid, β-sitosterol, caffeic acid, and hexadecanoic acid contained in R. ternatus are considered among its key active network pharmacology targets.

Saponins and Polysaccharides

RT contains various bioactive compounds, including alkaloids, fatty acids, polysaccharides, and saponins. Saponins have received growing research attention. Saponins represent structurally unique plant secondary metabolites that frequently serve as key pharmacologically active components, possessing well-documented anti-inflammatory and anticancer properties.

Other Isolated Compounds

Additional compounds isolated from R. ternatus roots by column chromatography include 1,2-benzenedicarboxylic acid dibutyl ester, glycerol-β-palmitate, glycerol-β-stearate, 2-amino-3-(3,4-dihydroxyphenyl)propanoic acid methyl ester, 2-amino-3-(3,4-dihydroxyphenyl)propanoic acid ethyl ester, 5-hydroxymethyl furaldehyde, 5-hydroxymethyl furoic acid, and vittadinoside.

Ranunculin and Protoanemonin

As a member of the Ranunculaceae family, R. ternatus also contains the glycoside ranunculin, which is a constituent relevant to both safety and pharmacology. Protoanemonin (sometimes called anemonol or ranunculol) is a toxin whose glycosidic precursor ranunculin is found in many plants of the buttercup family (Ranunculaceae). When the plant is wounded or macerated, ranunculin is enzymatically broken down into glucose and protoanemonin. However, the traditional and pharmaceutical use of the dried root takes advantage of the fact that protoanemonin is subsequently polymerized to the inactive anemonin, the form found in dried plants.

4. Mechanisms of Action

Anti-Tumor and Pro-Apoptotic Mechanisms

Multiple molecular mechanisms have been investigated in preclinical models. In studies of colorectal cancer (CRC), RTAs (the alkaloid-rich fraction) act through a dual mechanism: (1) reducing TGF-β levels while decreasing Smad7 expression and upregulating Smad1 and Smad4, thereby limiting the formation of the Smad transcriptional complex; (2) downregulating Snail and CCL5 secretion, enhancing E-cadherin expression, and suppressing MMP3 and MMP9. This suppresses the epithelial-mesenchymal transition (EMT), which is the primary driver of cancer cell invasion and metastasis.

In cell line studies of lymphoma, to test the apoptosis induction ability of the ethyl acetate extract (RTE), researchers analyzed phosphatidylserine exposure, DNA fragmentation, and caspase cleavage. RTE induced phosphatidylserine exposure and caspase-7 cleavage, but not caspase-3 cleavage. Sub-G1 cells were accumulated but DNA fragmentation was not observed. A pan-caspase inhibitor Z-Asp-CH2-DCB suppressed RTE-induced caspase cleavage and the above-described events.

For breast cancer, a JAK/STAT pathway mechanism has been proposed. A Kyoto Encyclopedia of Genes and Genomes analysis showed that the Janus kinase/signal transducer and activator of transcription signaling pathway might be associated with the anti-BC effects of RT. In vivo and in vitro experiments showed that total saponins from RT had a good anti-BC effect that can inhibit the expression of JAK2 and STAT3-related proteins.

Anti-Inflammatory Mechanisms

The constituents of R. ternatus contribute to its diverse pharmacological properties, such as expectorant, anti-inflammatory, detoxifying, and anti-edema effects. In renal models, Ranunculus ternatus was reported to prevent renal injury in ischemia-reperfusion acute kidney injury (IR-AKI) mice; the mechanism may be related to the inhibition of inflammatory response by downregulating the expression of TNF-α, trimethylation of Histone H3 lysine 36 (H3K36me3), and trimethylation of Histone H3 lysine 4 (H3K4me3).

In a diabetic nephropathy (DN) mouse model, the expression levels of Vimentin, α-SMA, TNF-α, NF-κB p-p65, NF-κB p65, SMYD2, H3K36me3, and H3K4me3 were determined by western blots. RTT extract significantly ameliorated renal injury and renal fibrosis in the renal tissue of STZ-induced diabetic mice, as demonstrated by the decreased expression level of Fibronectin (65%), Vimentin and α-SMA (75% & 53%).

Hepatoprotective and Anti-Fibrotic Mechanisms

In liver fibrosis research, the key active constituent identified is β-sitosterol: β-sitosterol, a major constituent of Ranunculus ternatus Thunb., has confirmed therapeutic value in hepatic fibrosis and has identified underlying mechanisms. After treatment with β-sitosterol, CCl4-induced hepatic fibrosis was reversed in mice, while inflammatory and hepatic fibrosis indices were improved.

Network pharmacology and transcriptomic profiling indicate that the MK3-NF-κB pathway is a key target: RTT's potential for treating liver fibrosis was examined using a network pharmacology approach, analyzing RTT's key bioactive components and their targets using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP).

Anti-Tuberculosis Mechanisms

Protoanemonin's ability to inhibit both gram-positive and gram-negative bacteria is linked to the presence of a 5-membered lactone ring with a highly reactive double bond system. However, specific anti-mycobacterial mechanisms attributed to R. ternatus extracts in isolation go beyond this single compound. Anti-tuberculosis research on the root has examined multiple extract fractions. Anti-tuberculosis activity of its water extract (WE), 70% ethanol extract (EE), water-eluted part of EE from D101 macroporous resin (WEPMR), and 70% ethanol-eluted part of EE from D101 macroporous resin (EEPMR) was conducted using H37Rv. Then EEPMR of better anti-tuberculosis activity was chosen to carry out anti-tuberculosis activity testing against MDR2314-2 and XDR1220.

5. Scientific Evidence by Area of Use

5.1 Oncology — Anti-Cancer Research

Anti-cancer activity represents the area of most intensive scientific investigation for catlaw buttercup. To date, traditional Chinese medicine containing R. ternatus has been reported to be effective against malignant lymphoma, leukemia, pulmonary tuberculosis, breast tumor, goiter, lung, gastric, and esophageal tumors. Critically, the bulk of the scientific evidence base consists of in vitro cell studies, network pharmacology analyses, and in vivo animal models — not human clinical trials.

Colorectal Cancer (CRC)

A 2025 study published in Phytomedicine provides the first experimental evidence that RT exerts anti-metastatic effects against CRC. The bioactive alkaloid fraction (RTAs) mitigates CRC progression and metastasis by regulating the EMT process, highlighting its potential. The study employed HCT116 and CT26 cell lines alongside ectopic tumor-bearing mouse models. The chemical composition of the active fraction was characterized by UPLC-Q-TOF/MS analysis. Transcriptomics profiling integrated with KEGG pathway enrichment analysis was performed, followed by core target prediction using CytoHubba and MCODE algorithms. RT-PCR, ELISA, and Western Blot assays were employed for target validation. This is preclinical evidence only; no human clinical trials for CRC have been reported.

Breast Cancer

A study investigating the anti-breast cancer mechanisms of Ranunculus ternatus employed an integrated strategy that included initial phytochemical characterization using HPLC-MS, identifying 53 bioactive metabolites in RT extracts. A mouse model of breast cancer created by cellular injection and MCF-7 cells were used as research objects for in vivo and in vitro validation experiments to study the anti-BC mechanism of RT. Recent research has shown that RT can effectively inhibit MCF-7 BC cell proliferation and induce their apoptosis. This is preclinical evidence only.

Lymphoma (T-Cell)

An in vitro study demonstrated by MTT assay that ethyl acetate extract (RTE) from R. ternatus exerts cytotoxic effects on human T cell lymphoma Jurkat cells. This study was carried out in cell culture and has not been extended to clinical trials.

Gastric Cancer

Research has investigated radix Ranunculus ternati saponins (RRTS) in human gastric cancer. RRTS, one of the main constituents extracted from the popular traditional Chinese medicine Radix Ranunculi ternati, has been reported to have various biological activities including anti-cancer effect. A study investigated the effect of RRTS on cell proliferation and apoptosis in human gastric adenocarcinoma SGC-7901 cells. Again, this is preclinical (in vitro) evidence.

Overall evidence strength for anti-cancer applications: All current anti-cancer evidence for catlaw buttercup root is at the preclinical stage — in vitro cell studies and in vivo murine models. RT has received widespread attention for its significant anti-tumor effects, but research on its anti-cancer mechanism and specific pharmacodynamic substances is relatively limited. No controlled human clinical trials have been published evaluating R. ternatus extract as a standalone anti-cancer treatment in human populations.

5.2 Tuberculosis and Antimicrobial Activity

The roots of Ranunculus ternatus (RT) are widely used because of their anti-inflammatory activity and ability to treat multi-drug resistant diseases, especially in the treatment of lymphatic tuberculosis in China, indicating that RT may have potential therapeutic value.

Currently, the roots of Ranunculus ternatus (RT) are mainly used to cure lymphatic tuberculosis and cancer in China with positive curative effects. However, systematic reviews and large-scale randomized controlled trials are lacking. The anti-tuberculosis evidence rests substantially on in vitro susceptibility testing of extracts against Mycobacterium tuberculosis strains, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, as described above.

In recent years, the infection rate of drug-resistant tuberculosis has gradually increased, but new anti-tuberculosis drugs are scarce. The task of tuberculosis prevention and control has become increasingly arduous. Researchers have pointed to catlaw buttercup's traditional clinical use for tuberculosis as a rationale for modern investigation, but human trial evidence remains very limited.

Evidence strength for tuberculosis: Preliminary. Based primarily on in vitro antimycobacterial testing, in vivo animal models, and a long tradition of clinical use in TCM settings. No rigorous randomized controlled clinical trials are available in the peer-reviewed literature.

5.3 Liver Fibrosis

RTT's potential for treating liver fibrosis has been examined using a network pharmacology approach. The key finding was that β-sitosterol, a major constituent of Ranunculus ternatus Thunb., has confirmed therapeutic value in hepatic fibrosis, and after treatment with β-sitosterol, CCl4-induced hepatic fibrosis was reversed in mice, while inflammatory and hepatic fibrosis indices were improved.

Evidence strength for liver fibrosis: Preclinical only (network pharmacology and murine CCl4 model). No human clinical data available.

5.4 Diabetic Nephropathy / Renal Fibrosis

Ranunculus ternatus Thunb. (RTT) is used clinically for the treatment of tuberculosis or as tumour adjuvant therapy, but its potential effect on diabetic nephropathy (DN) has not been formally studied until recently. Researchers investigated the effect of RTT extract in renal fibrosis of DN. In the preclinical study, C57BL/6 mice were randomly divided into four groups (n = 12). Diabetes mellitus mice were induced by streptozotocin (STZ, 55 mg/kg/day) for five consecutive days and treated by RTT extract (2 g/kg). RTT extract significantly ameliorated renal injury and renal fibrosis in the renal tissue of STZ-induced diabetic mice as demonstrated by the decreased expression level of Fibronectin (65%), Vimentin and α-SMA (75% & 53%).

A broader systematic review of TCM for diabetic kidney disease noted that Ranunculus ternatus Extract (RTT) reduces the expression levels of TNF-α, SET, and MYND Domain Containing Protein 2 (SMYD2).

Evidence strength for diabetic nephropathy: Preclinical only (murine STZ-induced diabetes model). No human clinical data available.

5.5 Thyroid Carcinoma

Network pharmacology methods have been applied to investigate catlaw buttercup against thyroid carcinoma. Its roots are widely used because of their anti-inflammatory activity and ability to treat multi-drug resistant diseases, and RT may have potential therapeutic value. These studies are computational and hypothesis-generating in nature and have not been validated in clinical trials.

Evidence strength for thyroid carcinoma: Very preliminary. Network pharmacology and molecular docking only; no in vivo or clinical confirmation.

5.6 Immune Regulation

The pharmacological activity of RRT includes immune regulation, anti-tumour, anti-tuberculosis, antioxidant, antibacterial, hepatoprotective, and anti-inflammatory effects. Immune modulation studies have been conducted in rat models of tuberculosis, where the effects of R. ternatus extract on cell-mediated immunity were investigated. The study aimed to investigate the effects of Radix Ranunculi Ternati, Radix Sophorae Flavescentis, Prunella Vulgaris L. and Stellera Chamaejasme L. extracts on cell-mediated immunity in a rat model of tuberculosis induced by multiple drug-resistant bacilli. The bacterium was isolated from patients infected with pulmonary tuberculosis. The immunological response in humans following infection with Mycobacterium tuberculosis involves a number of cytokines, including IFN-γ and IFN-α, which are important for killing intracellular micro-organisms.

Evidence strength for immune regulation: Preliminary. Evidence is from in vitro and animal models, with no established clinical data for standalone immune modulation in humans.

6. Body Systems Associated with Catlaw Buttercup

Based on the available research literature, the body systems most consistently associated with catlaw buttercup root are:

Respiratory system: Traditional use for cough, phlegm, pulmonary tuberculosis, laryngitis, and lung cancer. R. ternatus plays a vital role in relieving cough and softening phlegm.
Lymphatic / immune system: Central to its historical use; primary traditional indication is lymphatic tuberculosis and lymph node swelling. The roots are mainly used to cure lymphatic tuberculosis and cancer in China.
Hepatic system: Preclinical research links β-sitosterol from RT to hepatic fibrosis reversal.
Renal system: Animal research demonstrates efficacy against renal fibrosis in a model of diabetic nephropathy.
Oncological (multi-system): Traditional Chinese medicine containing RT has been reported to be effective against malignant lymphoma, leukemia, pulmonary tuberculosis, breast tumor, goiter, lung, thyroid, gastric, and esophageal tumor.
Skin (topical, traditional): Folk use for furunculosis and poisonous swelling.

7. Dosage Forms and Dosages Reported in Research

No universally standardized human clinical dosage has been established for catlaw buttercup root extract, and the following reflect doses employed in studies only:

Animal study (diabetic nephropathy model): RTT extract was administered at 2 g/kg to C57BL/6 mice induced with streptozotocin.
Extract standardization (commercial): Products are formulated to alkaloid concentrations of 3%, 4%, or 5%, or in concentrated dry extract ratios of 4:1, 5:1, 10:1, and 20:1.
TCM pharmaceutical preparations: Preparations recorded in Chinese patent medicine prescriptions with R. ternatus as the main ingredient include Maozhuacao Capsule and Yifei Zhike Capsule; Maozhuacao Capsule is a pure TCM preparation made from the pellets of R. ternatus extracted by modern purification technology. Specific dose amounts in milligrams per capsule are not reported in the available peer-reviewed literature.

No peer-reviewed human clinical trial has established a recommended human dose, dose range, or pharmacokinetic profile for catlaw buttercup root extract as a standalone dietary supplement.

8. Safety Considerations

Ranunculin and Protoanemonin: The Fresh Plant Risk

The central safety consideration for all Ranunculus species, including R. ternatus, is the presence of the glycoside ranunculin and its toxic hydrolysis product. Ranunculus ternatus contains ranunculin, which breaks down into protoanemonin, causing severe skin irritation upon contact. Ingestion of buttercup genus plants can result in blistering of the mouth, bloody diarrhea, and extreme salivation.

Intoxications caused by Ranunculus are due mainly to the irritant effects of protoanemonin. Formed from glycosides such as ranunculin when plant tissues are macerated, protoanemonin is a potent vesicant that primarily irritates the mucous membranes of the digestive system. Effects on the urinary system, mammary glands, and brain associated with ingestion of especially large amounts of plant material also have been reported. Protoanemonin is subsequently polymerized to the inactive anemonin, the form found in dried plants.

This is the critical safety distinction: the dried plant is non-toxic with respect to protoanemonin formation, because drying converts the reactive protoanemonin into its innocuous dimer anemonin. All parts of some Ranunculus species are poisonous when fresh; however, the plant is used in folk medicine to treat various diseases after heating or drying.

Systemic Effects of Ingestion of Fresh Material

Protoanemonin has vesicant properties, which cause rashes or blistering upon contact with the skin or mucosa. Ingesting large amounts of the toxin, despite its bitter taste, can cause nausea, vomiting, dizziness, spasms, acute hepatitis, jaundice, or paralysis in animals and humans.

Ranunculus species vary in their levels of this toxic compound, and individual plants are said to be more toxic in the spring when they are actively growing and flowering. Protoanemonin breaks down further into an innocuous compound called anemonin, so dead and dried-out plants are generally safe.

Safety of Processed/Dried Root

Catclaw buttercup root extract has been used in traditional medicine for centuries, suggesting a degree of safety when used appropriately. However, modern scientific studies on its long-term safety in humans are limited. The extract's low toxicity to normal cells, as observed in cancer studies, is encouraging, but more comprehensive safety evaluations are needed.

TCM Contraindication

TCM literature specifies a clear, historically recognized contraindication: it can be used when lymphatic tuberculosis has not ulcerated, but it cannot be used after it has ulcerated, as this may turn into sores. This guidance highlights that even within traditional practice, the herb's irritant potential was acknowledged and managed by restricting its use when tissue integrity was compromised.

Protoanemonin's Antimicrobial Properties

While primarily known for its toxicity, protoanemonin also has documented antimicrobial properties that may contribute to the herb's traditional uses. Protoanemonin's ability to inhibit both gram-positive and gram-negative bacteria is linked to the presence of a 5-membered lactone ring with a highly reactive double bond system. Additionally, the two ranunculins, protoanemonin and anemonin, have shown fungicidal, antimicrobial, antimutanenic, and antipyretic properties, and have been used for ethnopharmacological purposes in many countries.

Absence of Drug Interaction Data

No peer-reviewed studies specifically characterizing pharmacokinetic or pharmacodynamic interactions between catlaw buttercup root extract and pharmaceutical drugs have been identified in the available literature. Given that constituents such as β-sitosterol are known to influence cholesterol metabolism pathways, and that alkaloid-containing extracts may interact with hepatic enzymes, potential interactions cannot be excluded. The absence of published interaction data should be noted as a gap, not as evidence of safety.

9. Evidence Summary and Research Gaps

Catlaw buttercup root (Radix Ranunculi ternati) has a well-documented position in traditional Chinese medicine, official pharmacopoeia recognition in China since 1977, and an expanding modern scientific literature investigating its phytochemistry and pharmacology. The pharmacological activity of RRT includes immune regulation, anti-tumour, anti-tuberculosis, antioxidant, antibacterial, hepatoprotective, and anti-inflammatory effects. This plant is especially effective in the treatment of cancer, tuberculosis, thyroid, and nasopharyngeal disorders — though this assertion, from a 2022 review, largely reflects preclinical findings rather than established clinical efficacy.

The dried root tuber of Ranunculus ternatus Thunb., a clinically utilized botanical drug in traditional Chinese medicine, remains largely underexplored in modern pharmacological research despite its documented efficacy. The entire body of scientific evidence for catlaw buttercup root as a dietary supplement or natural therapeutic agent in humans consists of in vitro cell studies, murine animal models, network pharmacology analyses, and traditional clinical use reports — predominantly from Chinese academic and medical institutions. There are no published Phase I, II, or III clinical trials in Western databases evaluating catlaw buttercup root extract for any condition in human subjects, and no established evidence-based dosage, safety profile, or efficacy claim for human use as a dietary supplement is supported by the peer-reviewed clinical trial literature.